Deputy Attorney General Gary G. Grindler addressed the National Institute on Health Care Fraud on May 13, 2010 to discuss Obama Administration efforts to combat health fraud. In addition to discussing health reform legislation and the Health Care Fraud Prevention and Enforcement Action Team, he highlighted other ways DOJ “is seeking to combat crimes relating to the healthcare and pharmaceutical industries.” For instance, according to Mr. Grindler, the DOJ expects to increase the use of the Foreign Corrupt Practices Act (FCPA) to prosecute kickbacks and bribes paid to foreign government officials by pharmaceutical companies, given that “in some foreign countries, nearly every aspect of the approval, manufacture, import, export, pricing, sale and marketing of a drug product may involve a “foreign official” within the meaning of the FCPA.” He warned that DOJ “will not hesitate to charge pharmaceutical companies and their senior executives under the FCPA if warranted to root out foreign bribery in the industry.” The DOJ also will continue to focus on intellectual property theft involving the pharmaceutical industry, including efforts to combat the sale of counterfeit and dangerous drugs.